1. <smlcap>L</smlcap>-Carnitine Ameliorates <smlcap>L</smlcap>-Asparaginase-Induced Acute Liver Toxicity in Steatotic Rat Livers
- Author
-
Anne Roesmann, Jens Panse, Albrecht Eisert, Mamdouh Afify, Rene Tolba, and Julia Steitz
- Subjects
Pharmacology ,Chemotherapy ,Asparaginase ,Portal venous pressure ,medicine.medical_treatment ,Glutamate dehydrogenase ,General Medicine ,Biology ,chemistry.chemical_compound ,Infectious Diseases ,Oncology ,chemistry ,Biochemistry ,Lactate dehydrogenase ,Drug Discovery ,Toxicity ,medicine ,Pharmacology (medical) ,Carnitine ,Cytotoxicity ,medicine.drug - Abstract
Background: Chemotherapy with L-asparaginase is associated with hepatotoxicity resulting in organ dysfunction in patients with preexisting liver disorders. This study investigated the protective effect of L-carnitine during chemotherapy in a steatotic rat liver model. Methods: Livers from nonsteatotic and steatotic rats were tested in an isolated liver reperfusion model adding L-asparaginase and L-carnitine to the reperfusate. Portal venous pressure (PVP), hepatic oxygen consumption, aspartate aminotransferase, lactate dehydrogenase, glutamate dehydrogenase and α-glutathione S-transferase levels were assessed. Further histopathological analysis was performed and cytotoxicity was verified in vitro. Results:L-Asparaginase induced toxicity in fatty livers whereas low toxicity was observed in normal livers. L-Carnitine induced a decline in PVP and oxygen consumption, and reduced parenchymal and mitochondrial damage in fatty livers. Cytotoxicity of L-asparaginase was not impaired by the presence of L-carnitine. Conclusions: Our study emphasizes the potential of L-carnitine to reduce L-asparaginase-induced hepatotoxicity in patients with preexisting liver disorders.
- Published
- 2013
- Full Text
- View/download PDF